GlassScriptPhysician profile
Olga Thon
NPI 1316231822
$113,411.53
in general payments reported to CMS, 2019-2025
30 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $1,220 · 2021: $8,644 · 2022: $23K · 2023: $18K · 2024: $28K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Honoraria: $16K · Consulting Fee: $7,535 · Food and Beverage: $4,358 · Travel and Lodging: $3,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,450.00 |
| Honoraria | $15,950.00 |
| Consulting Fee | $7,535.00 |
| Food and Beverage | $4,358.42 |
| Travel and Lodging | $3,327.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $40,115.24 | 2022-2023 | Uplizna |
| Amgen INC. | $36,816.45 | 2021-2025 | Uplizna |
| Genentech USA, INC. | $14,596.89 | 2019-2025 | Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $12,047.23 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $6,156.31 | 2019-2025 | Tysabri, Vumerity |
| Genentech, INC. | $1,299.75 | 2020-2021 | |
| Celgene Corporation | $273.04 | 2021-2025 | Zeposia |
| Emd Serono, INC. | $190.21 | 2023-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $189.34 | 2023-2025 | Rystiggo, Briviact, Nayzilam |
| Boston Scientific Corporation | $153.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $140.08 | 2022 | |
| Philips North America LLC | $132.27 | 2022-2025 | (5044) Mcot, Mcot |
| Depuy Synthes Sales INC. | $120.00 | 2025 | Embotrap |
| E.R. Squibb & Sons, L.L.C. | $119.96 | 2020-2021 | |
| Greenwich Biosciences, INC. | $116.42 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $115.67 | 2024 | |
| Abbvie INC. | $111.63 | 2024-2025 | |
| Portola Pharmaceuticals, LLC | $110.19 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $107.05 | 2021 | |
| Sk Life Science, INC. | $104.16 | 2023 | Xcopri |
| Lundbeck LLC | $80.65 | 2019-2025 | Vyepti |
| Argenx US, INC. | $52.11 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Janssen Biotech, INC. | $51.46 | 2025 | |
| Merz Pharmaceuticals, LLC | $45.97 | 2025 | Xeomin, Inbrija |
| Neurocrine Biosciences, INC. | $40.33 | 2025 | |
| Pfizer INC. | $39.18 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $31.46 | 2024-2025 | Austedo Xr, Austedo Xr |
| Csl Behring | $21.54 | 2025 | Hizentra |
| Ani Pharmaceuticals, INC. | $19.50 | 2024 | Purified Cortrophin Gel |
| Amneal Pharmaceuticals LLC | $14.25 | 2024 | Ongentys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Thon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.